首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   684篇
  免费   78篇
  国内免费   8篇
耳鼻咽喉   3篇
儿科学   66篇
妇产科学   6篇
基础医学   95篇
口腔科学   30篇
临床医学   71篇
内科学   146篇
皮肤病学   19篇
神经病学   24篇
特种医学   133篇
外科学   41篇
综合类   42篇
预防医学   28篇
眼科学   29篇
药学   12篇
肿瘤学   25篇
  2023年   1篇
  2022年   2篇
  2021年   4篇
  2020年   6篇
  2019年   7篇
  2018年   19篇
  2017年   7篇
  2016年   21篇
  2015年   22篇
  2014年   26篇
  2013年   41篇
  2012年   19篇
  2011年   17篇
  2010年   46篇
  2009年   47篇
  2008年   16篇
  2007年   26篇
  2006年   14篇
  2005年   18篇
  2004年   7篇
  2003年   12篇
  2002年   6篇
  2001年   7篇
  2000年   4篇
  1999年   5篇
  1998年   40篇
  1997年   42篇
  1996年   42篇
  1995年   36篇
  1994年   22篇
  1993年   28篇
  1992年   4篇
  1991年   8篇
  1990年   6篇
  1989年   18篇
  1988年   15篇
  1987年   10篇
  1986年   13篇
  1985年   14篇
  1984年   7篇
  1983年   12篇
  1982年   5篇
  1981年   13篇
  1980年   7篇
  1979年   4篇
  1978年   4篇
  1977年   8篇
  1976年   9篇
  1975年   2篇
  1884年   1篇
排序方式: 共有770条查询结果,搜索用时 25 毫秒
111.
112.
Delore V  Salamand C  Marsh G  Arnoux S  Pepin S  Saliou P 《Vaccine》2006,24(10):1586-1592
Safety data on the inactivated split influenza vaccine, Vaxigrip, were compiled and analysed from 28 clinical trials (total: 4599 subjects aged 6 months to 99 years) to provide a robust estimate of the reactogenicity profile. The most frequent solicited reactions were non-severe injection site pain and erythema in children, adults, and elderly. Mild or moderate fever was the most frequent reaction in 6-36 months olds; few systemic reactions were reported in older groups. Reactogenicity was comparable in healthy and high-risk children. The long-term experience with the world's most widely used influenza vaccine, Vaxigrip, confirms its excellent tolerability, and supports its continued use in clinical practice worldwide.  相似文献   
113.
114.
In 2001, one of the authors wrote in the Medical Journal of Australia about trachoma explaining that Australia is the only developed country in the world where blinding trachoma still exists. Ten years later, the same is still true, but there is some progress and the situation in Australia is starting to change. However, this progress has been somewhat glacial, especially compared with the rapid changes being made in other ‘undeveloped’ parts of the world.  相似文献   
115.

Background  

This study evaluates the existence of numerical alterations of chromosome 17 and TP53 gene deletion in gastric adenocarcinoma. The p53 protein expression was also evaluated, as well as, possible associations with clinicopathological characteristics.  相似文献   
116.

Background and purpose:

The aim of the current study was to investigate the role of arachidonic acid (AA) metabolism via cyclooxygenase (COX) in the endothelial dysfunction of penile arteries from pre-diabetic, obese Zucker rats (OZR).

Experimental approach:

Penile arteries from OZR and from lean Zucker rats (LZR) were mounted in microvascular myographs to assess vascular function and COX expression was determined by immunohistochemistry.

Key results:

Acetylcholine (ACh) and AA elicited relaxations that were impaired in arteries from OZR. Inhibition of both COX-1 and COX-2 reduced the relaxant effects of ACh and AA in LZR but not in OZR. Inhibitors of COX-1 and of the TXA2/PGH2 (TP) receptor enhanced the relaxations induced by AA in both LZR and OZR, whereas COX-2 inhibition enhanced these responses only in OZR. TP receptor blockade did not restore ACh relaxant responses in arteries from OZR. Inhibition of COX-1 increased basal tension in OZR and this contraction was blunted by TP receptor blockade. The vasoconstrictor responses to noradrenaline were augmented by indomethacin and by COX-2 inhibition in LZR but not in OZR. Immunohistochemical staining showed that both COX-1 and COX-2 are expressed in the endothelium of penile arteries from both LZR and OZR.

Conclusions and implications:

Vasoactive prostanoids were formed via constitutively active COX-1 and COX-2 pathways in normal rat penile arteries. Under conditions of insulin resistance, the release and/or effects of vasodilator prostanoids were impaired, contributing to the blunted endothelium-dependent vasodilatation and to the enhanced vasoconstriction.  相似文献   
117.
Cipriano GFB, Peres PAT, Cipriano G Jr, Arena R, Carvalho AC. Safety and cardiovascular behavior during pulmonary function in patients with Marfan syndrome. Marfan syndrome (MS) is a dominant autosomal connective tissue disease that impacts multiple systems, such as the cardiovascular system, tissue viscoelastic properties, bone calcification matrix and, most specific to the present investigation, pulmonary parenchyma. The aim of the present study was to evaluate pulmonary function (PF) in patients with MS and relate it to thoracic cage abnormalities (TCA) and the occurrence of cardiac arrhythmias during the spirometric exam (SE). A sample of 75 subjects (46 with MS) underwent clinical, anthropometric, echocardiographic, radiographic and PF evaluation; 51 subjects (33 with MS) had their electrocardiogram (ECG) information evaluated during PF. These individuals were matched and compared with a healthy control group (CG). Forced vital capacity (FVC) and forced expiratory volume (FEV) in the first second (FEV1) in the patients with MS were significantly lower in comparison with the CG (p = 0.012 and 0.0006) and predicted values (p = 0.04 and 0.003). Subgroup analysis based on TCA revealed differences between patients with MS with two combined abnormalities (scoliosis + pectus) in comparison with both the CG (p = 0.012 and 0.002) and patients without abnormalities (p = 0.05 and 0.006). There were no differences regarding the occurrence of arrhythmia during exertion on the SE. There was a correlation between clinical history, cardiovascular behavior and PF. PF is reduced in patients with MS, and deformities in the thoracic cage appear to contribute to this reduction. Despite the apparent structural alterations in the cardiovascular system in this population, exertion during the SE appears to be safe.  相似文献   
118.
119.
120.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号